Kite Pharma, a Gilead company, announced that the marketing authorization in Japan for Yescarta, a chimeric antigen receptor, or CAR, T-cell therapy, has been transferred from Daiichi Sankyo to Gilead Sciences K.K., the Japan subsidiary of Gilead Sciences.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GILD: